COMMUNIQUÉS West-GlobeNewswire

Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
22/04/2024
– Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic disease and neurology – – Company to host symposium on “Advancing Gene Therapy for Common Diseases [...]
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
22/04/2024
Spotlight on new, second-generation, TRACER™-derived AAV capsids; translatability as evidenced by cross-species and receptor data; and activity against therapeutic targets in Alzheimer’s disease and ALS LEXINGTON, Mass [...]
Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs)
22/04/2024
Cette nouvelle approche d'édition pourrait être utilisée pour développer de nouveaux traitements pour les maladies métaboliques et neurologiques L'utilisation d'ADN simple brin circulaire associée à l'édition du génome [...]
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
22/04/2024
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
22/04/2024
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell [...]
Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting
22/04/2024
- Oral presentation to highlight proof-of-concept efficacy in reducing HBV biomarkers in serum and intrahepatic HBV in vivo SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, [...]
Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting
22/04/2024
SOMERVILLE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, [...]
GeneFab Announces Two Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024
22/04/2024
– Two accepted abstracts highlight innovative methods for gene expression regulation – – GeneFab’s synthetic biology capabilities and Advanced Therapies offerings enable development of affordable therapies globally with [...]
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
22/04/2024
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]
Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
22/04/2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced that it will release financial results for the first quarter of [...]
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
22/04/2024
ALISO VIEJO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Streamline Health® To Report Fourth Quarter and Fiscal Year 2023 Financial Performance
22/04/2024
Atlanta, GA, April 22, 2024 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM) , a leading provider of solutions that enable healthcare providers to proactively address [...]
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22/04/2024
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies related to clinical efficacy or clinical safety data in BLA, and no new clinical studies [...]
OrthoPediatrics Corp. to Report First Quarter 2024 Financial Results on May 7, 2024
22/04/2024
WARSAW, Ind., April 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
ArriVent Appoints Kristine Peterson to its Board of Directors
22/04/2024
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. , a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced [...]
Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer
22/04/2024
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company, today announced the [...]
Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
22/04/2024
MELBOURNE, Australia, April 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in [...]
GLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENT
22/04/2024
Rutherford, NJ, April 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
22/04/2024
COPENHAGEN, Denmark, April 22, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]

Pages